MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism
MDMX is overexpressed in the vast majority of patients with acute myeloid leukemia (AML). We report that MDMX overexpression increases preleukemic stem cell (pre-LSC) number and competitive advantage. Utilizing five newly generated murine models, we found that MDMX overexpression triggers progressio...
Main Authors: | Ueda, K, Kumari, R, Schwenger, E, Wheat, JC, Bohorquez, O, Narayanagari, S-R, Taylor, SJ, Carvajal, LA, Pradhan, K, Bartholdy, B, Todorova, TI, Goto, H, Sun, D, Chen, J, Shan, J, Song, Y, Montagna, C, Xiong, S, Lozano, G, Pellagatti, A, Boultwood, J, Verma, A, Steidl, U |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Cell Press
2021
|
Similar Items
-
Preleukemic stem cells: leave it or not?
by: Minhua Su, et al.
Published: (2020-04-01) -
Induction of AML Preleukemic Fusion Genes in HSPCs and DNA Damage Response in Preleukemic Fusion Gene Positive Samples
by: Pavol Kosik, et al.
Published: (2021-03-01) -
Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells
by: Shayda Hemmati, et al.
Published: (2017-11-01) -
Modelling the progression of a preleukemic stage to overt leukemia in children with down syndrome
by: Labuhn, M, et al.
Published: (2018) -
Chemical instability and promiscuity of arylmethylidenepyrazolinone-based MDMX inhibitors
by: Stefaniak, J, et al.
Published: (2018)